All In Biotech

Drug Trial Radar · NCT04685616

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,042 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,042

Planned (sponsor's estimate)

Start

Apr 14, 2022

Primary completion

Sep 2030

Study completion Sep 2032

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Takeda; University of Miami; European Organisation for Research and Treatment of Cancer - EORTC; Australasian Leukaemia and Lymphoma Group; Seagen Inc.; Canadian Cancer Trials Group
First posted
Dec 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.

Conditions

  • Hodgkin Lymphoma

Interventions

  • Involved site radiotherapyRadiation

    Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines. Recommended dose 30Gy

  • DoxorubicinDrug

    See arm description

  • BleomycinDrug

    See arm description

  • Brentuximab vedotinDrug

    See arm description

  • VinblastineDrug

    See arm description

  • DacarbazineDrug

    See arm description

  • Haematopoietic growth factorDrug

    See arm description

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: 3 years from end of treatment

Locations

72 sites in 12 countries. Site status is shown where the registry gives one.

  • Stanford University - (Stanford Cancer Institute)

    Stanford, California · Recruiting

  • University of Miami School of Medicine

    Miami, Florida · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Royal Adelaide Hospital

    Adelaide, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Australia · Recruiting

  • Royal Brisbane and Women's Hospital

    Brisbane, Australia · Recruiting

  • Royal Darwin Hospital

    Darwin, Australia · Recruiting

  • Liverpool Hospital

    Liverpool, Australia · Recruiting

  • Sunshine Hospital (Western Health)

    Melbourne, Australia · Recruiting

  • Concord Repatriation General Hospital

    Sydney, Australia · Recruiting

  • St George Hospital

    Sydney, Australia · Recruiting

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia · Recruiting

  • Townsville University Hospital

    Townsville, Queensland, Australia · Recruiting

  • Universitair Ziekenhuis Antwerpen

    Antwerp, Belgium · Recruiting

  • Ziekenhuis Netwerk Antwerpen

    Antwerp, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • CHU-UCL Namur

    Namur, Belgium · Recruiting

  • AZ Delta Campus Rumbeke

    Roeselare, West Flanders, Belgium · Recruiting

  • Ottowa Hospital Research Institute

    Ottawa, Canada · Recruiting

  • Saint John Regional Hospital

    Saint John, Canada · Recruiting

  • University Health Network Princess Margaret Cancer Centre

    Toronto, Canada · Recruiting

  • Vancouver Cancer Centre

    Vancouver, Canada · Recruiting

  • CancerCare Manitoba

    Winnipeg, Canada · Recruiting

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada · Recruiting

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada · Recruiting

  • Aarhus University Hospitak Skjeby

    Aarhus, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • St James's Hospital

    Dublin, Ireland · Recruiting

  • St. Vincent's University Hospital

    Dublin, Ireland · Recruiting

  • University Hospital Galway

    Galway, Ireland · Recruiting

  • Amsterdam UMC - location VUMC

    Amsterdam, Netherlands · Recruiting

  • Reinier de Graafweg 3-11 - Postbus 5011 - 2625 AD Delft

    Delft, Netherlands · Recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands · Recruiting

  • Radboud University Medical Center Nijmegen

    Nijmegen, Netherlands · Recruiting

  • NL 331 - Haaglanden Medisch Centrum (HMC) - Haaglanden MC

    The Hague, Netherlands · Recruiting

  • Auckland City Hospital

    Auckland, New Zealand · Recruiting

  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil

    Lisbon, Portugal · Recruiting

  • Narodny Onkologicky Ustav

    Bratislava, Slovakia · Recruiting

  • Hospital Del Mar

    Barcelona, Spain · Recruiting

  • Institut Catala d'Oncologia

    Barcelona, Spain · Recruiting

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.